<SEC-DOCUMENT>0001708599-24-000033.txt : 20241226
<SEC-HEADER>0001708599-24-000033.hdr.sgml : 20241226
<ACCEPTANCE-DATETIME>20241223195058
ACCESSION NUMBER:		0001708599-24-000033
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20241223
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241226
DATE AS OF CHANGE:		20241223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Serina Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001708599
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				821436829
		STATE OF INCORPORATION:			AL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38519
		FILM NUMBER:		241575353

	BUSINESS ADDRESS:	
		STREET 1:		601 GENOME WAY
		STREET 2:		SUITE 2001
		CITY:			HUNTSVILLE
		STATE:			AL
		ZIP:			35806
		BUSINESS PHONE:		(256) 327-9630

	MAIL ADDRESS:	
		STREET 1:		601 GENOME WAY
		STREET 2:		SUITE 2001
		CITY:			HUNTSVILLE
		STATE:			AL
		ZIP:			35806

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AgeX Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170606
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ser-20241223.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:9a5b1713-d2e0-49d4-bf5c-be109325aa8a,g:e2c6af3d-8447-4c77-a992-13dbd7e88f3c,d:9ac5aa1deb4b4ca38821eaa2e0757eb5-->
<html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ser-20241223</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-23">0001708599</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-24">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ser-20241223.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001708599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-13</xbrli:startDate><xbrli:endDate>2024-12-13</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i9ac5aa1deb4b4ca38821eaa2e0757eb5_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (date of earliest event reported): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">December&#160;23, 2024</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Serina Therapeutics, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">1-38519</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">82-1436829</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(IRS Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">601 Genome Way</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 2001</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Huntsville</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-10">Alabama</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">35806</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">(256)</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">327-9630</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-17">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.839%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.325%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Name of exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">SE</ix:nonNumeric>R</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">NYSE American</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-21">x</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-true" id="f-22">x</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i9ac5aa1deb4b4ca38821eaa2e0757eb5_84"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div id="i9ac5aa1deb4b4ca38821eaa2e0757eb5_7"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Explanatory Note</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 26, 2024, the Delaware corporation formerly known as &#8220;AgeX Therapeutics, Inc.&#8221; completed its previously announced merger transaction in accordance with the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated as of August 29, 2023 (the &#8220;Merger Agreement&#8221;), by and among AgeX Therapeutics, Inc. (&#8220;AgeX&#8221;), Canaria Transaction Corporation, a wholly owned subsidiary of AgeX (&#8220;Merger Sub&#8221;), and Serina Therapeutics, Inc. (&#8220;Legacy Serina&#8221;), pursuant to which Merger Sub merged with and into Legacy Serina, with Legacy Serina surviving the merger as a wholly owned subsidiary of AgeX (the &#8220;Merger&#8221;). Additionally, on March 26, 2024, AgeX changed its name from &#8220;AgeX Therapeutics, Inc.&#8221; to &#8220;Serina Therapeutics, Inc.&#8221; (the &#8220;Company&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.01 Entry into a Material Definitive Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-25">December&#160;23, 2024</ix:nonNumeric>, the Company entered into a Stock Purchase Agreement with JuvVentures (UK) Limited, a private limited company incorporated under the laws of England and Wales (&#8220;Juvenescence&#8221;), pursuant to which Juvenescence purchased all of the outstanding shares of UniverXome Bioengineering, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (&#8220;UniverXome&#8221;). </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UniverXome was formed by AgeX in August 2023. Prior to the closing of the Merger, AgeX transferred to UniverXome substantially all assets of AgeX (the &#8220;Legacy Assets&#8221;), other than certain biological materials. In consideration of the transfer of the Legacy Assets, UniverXome had assumed (i) all indebtedness of AgeX issued to Juvenescence, and secured by the Legacy Assets, that had not been previously converted into AgeX Series A Preferred Stock or AgeX Series B Preferred Stock, and (ii) all other liabilities of AgeX in existence as of the effective time of the Merger (other than certain transaction expenses related to the Merger).</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Legacy Assets included all of AgeX&#8217;s interests in ReCyte Therapeutics, Inc. (&#8220;ReCyte&#8221;), Reverse Bioengineering, Inc. (&#8220;Reverse Bio&#8221;) along with certain patents, patent applications, and other intellectual property, certain biological materials, certain trademarks and service marks, certain equipment, certain inventory, and certain files and records relating to the foregoing. UniverXome owns 94.8% of the outstanding capital stock of ReCyte. ReCyte owns certain pre-clinical research and development assets involving stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders and ischemic conditions. UniverXome owns 100% of the outstanding capital of Reverse Bio. Reverse Bio owns assets involved in partial cellular reprogramming using its iTR&#8482; technology with the intent to revert aged or diseased cells to a healthy and functional state. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the purchase of UniverXome, Juvenescence assumed approximately $11.2 million of secured debt owed by UniverXome to Juvenescence in addition to a nominal cash payment. The debt assumed by Juvenescence was secured by substantially all of the assets of UniverXome. The closing of the transaction occurred simultaneously with the execution of the Stock Purchase Agreement on <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-26">December&#160;23, 2024</ix:nonNumeric>. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the Stock Purchase Agreement is qualified in its entirety by reference to the agreement itself, which is filed as Exhibit 10.1 to this Current Report on Form 8-K.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Relationships between the Company and Juvenescence</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Juvenescence is the largest holder of the Company&#8217;s common stock and has appointed Greg Bailey and Richard Marshall as its designees to the Company&#8217;s Board of Directors. Additional information about the relationships among the Company, Juvenescence, and Messrs. Bailey and Marshall is described under note 4, Related Party Transactions, in the Notes to Condensed Consolidated Interim Financial Statements in the Company&#8217;s Quarterly Report on Form 10-Q for the period ended September 30, 2024, which description is hereby incorporated by reference.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the relationships among the Company, Juvenescence, and Messrs. Bailey and Marshall, in considering the Stock Purchase Agreement, on March 27, 2024, the Company&#8217;s Board of Directors established and delegated to a special committee comprised solely of independent and disinterested directors (the &#8220;Special Committee&#8221;) the power and authority to evaluate, negotiate and approve, or decline to approve, the Agreement and the related transactions. The Special Committee was composed of Balkrishan &#8220;Simba&#8221; Gill, Steven Ledger and J. Milton Harris. The Special Committee&#8217;s consideration of the Stock Purchase Agreement included obtaining an independent third party valuation of the assets of UniverXome. On <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-27">December&#160;23, 2024</ix:nonNumeric>, the Special Committee approved the execution and delivery by the Company of the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock Purchase Agreement and the related transactions, including for purposes of the Company&#8217;s Related Person Transaction Policy.</span></div><div id="i9ac5aa1deb4b4ca38821eaa2e0757eb5_10"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 2.01 Completion of Acquisition or Disposition of Assets.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The disclosures set forth in Item 1.01 above are incorporated by reference into this Item 2.01.</span></div><div><span><br/></span></div><div id="i9ac5aa1deb4b4ca38821eaa2e0757eb5_13"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 - Financial Statements and Exhibits.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Description</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="serinade-stockpurchaseagre.htm">Stock Purchase Agreement dated December 23, 2024, between Serina Therapeutics, Inc. and Juvenescence Limited.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cover Page Interactive Data File (embedded within the Inline XBRL document) </span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i9ac5aa1deb4b4ca38821eaa2e0757eb5_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.477%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">SERINA THERAPEUTICS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date: December&#160;23, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">/s/ Steve Ledger</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Executive Officer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>serinade-stockpurchaseagre.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="id066a6770d5a45aaae0e7263de11f130_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">STOCK PURCHASE AGREEMENT</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Stock Purchase Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), effective as of 11&#58;59 pm on December 23, 2024, is entered into between Serina Therapeutics, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Seller</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and JuvVentures (UK) Limited, a private limited company incorporated under the laws of England and Wales (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Further, Juvenescence Limited, a private limited company incorporated under the laws of the Isle of Man (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Juvenescence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), enters into this Agreement for the sole purpose of being bound by and receiving the benefits of Sections 5.02 and 5.05 of this Agreement.  </font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-bottom:11pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:7.31pt"> On August 30, 2023, AgeX Therapeutics, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AgeX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), caused the Certificate of Incorporation of UniverXome Bioengineering, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), to be filed with the Secretary of State of the State of Delaware. </font></div><div style="margin-bottom:11pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:7.92pt">On March 26, 2024, prior to the consummation of the Merger (defined below), AgeX entered into that certain Asset Contribution Agreement with the Company attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Asset Contribution Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), pursuant to which AgeX transferred to the Company all of AgeX&#8217;s capital stock in Reverse Bioengineering, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reverse Bio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and ReCyte Therapeutics, Inc., a California corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ReCyte</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), along with certain patents, patent applications, and other intellectual property, certain biological materials, certain trademarks and service marks, certain equipment, certain inventory, and certain files and records relating to the foregoing, and the Company assumed all of the Liabilities (as defined in the Asset Contribution Agreement) in existence as the Effective Time (as defined in the Merger Agreement).</font></div><div style="margin-bottom:11pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:7.92pt">The Seller has informed the Buyer that the transfer of the patents, patent applications, copyrights, and other intellectual property to the Company pursuant to the Asset Contribution Agreement was not perfected with the applicable Governmental Body (as defined below), that Seller has taken no action to perfect the transfer, and that Seller will cooperate with Buyer after the consummation of the transaction contemplated herein by executing such documents as Buyer and Seller agree are reasonably necessary to perfect the transfer at the appropriate governmental agencies, but that any such perfection will be at the cost of the Buyer. </font></div><div style="margin-bottom:11pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:7.31pt">Seller has further informed the Buyer that the Seller has limited knowledge of and experience with the assets of the Company and thus has made no representation or warranty, express or implied,  with respect to the assets of the Company except as expressly set forth herein, which such representations and warranties shall be deemed, as they relate to the Company&#8217;s properties and other assets, to be qualified in all instances by the Seller&#8217;s knowledge (except for the second sentence of Section 3.05 which representation is made without such knowledge qualification). </font></div><div style="margin-bottom:11pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.54pt">Concurrently with the execution of the Asset Contribution Agreement, Buyer, AgeX and AgeX&#8217;s subsidiaries, the Company, Reverse Bio, and ReCyte entered into that certain Agreement with Respect to the Convertible Notes attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Convertible Notes Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:11pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.14pt">Pursuant to the Convertible Notes Agreement, AgeX transferred to the Company, and the Company assumed, all of AgeX&#8217;s rights and obligations under the 2022 Note (as defined in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:11pt;padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the Convertible Notes Agreement) and 2023 Note (as defined in the Convertible Notes Agreement) and the other Secured Notes Loan Documents (as defined in the Convertible Notes Agreement) and the Buyer released the Seller from all security agreements, pledge agreements, guaranty agreements, as well as certain assets of the Seller.</font></div><div style="margin-bottom:11pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:7.31pt">Section 12 of the Convertible Notes Agreement created a Claim Reserve (as defined therein) to be funded by Buyer, which the Buyer and Seller desire to retain. </font></div><div style="margin-bottom:11pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">H.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:7.31pt">Section 13 of the Convertible Notes Agreement created an obligation on Buyer to fund certain Closing Cash (as defined therein), which the Buyer and Seller desire to release each other from any further obligation thereunder.  </font></div><div style="margin-bottom:11pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.59pt">Reverse Bio, ReCyte, and the Company have each granted a security interest in their Collateral (as defined in the Convertible Notes Agreement) to Buyer pursuant to that certain Amended and Restated Security Agreement, dated as of March 10, 2023 (as amended by that certain Joinder Agreement, dated as of November 9, 2023, and as may be further amended and restated, amended and restated, supplemented or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Subsidiary Security Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) among Reverse Bio and ReCyte, (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Subsidiary Obligors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), UniverXome, AgeX and Buyer.</font></div><div style="margin-bottom:11pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">J.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.97pt">The Company and the Subsidiary Obligors have each guaranteed the obligations of AgeX under the 2022 Note pursuant to that certain Guaranty Agreement, dated as of November 9, 2023 (as may be amended, restated, amended and restated supplemented or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Guaranty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), made by the Subsidiary Obligors in favor of Buyer.</font></div><div style="margin-bottom:11pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">K.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:7.31pt">On March 26, 2024, AgeX completed a merger transaction in accordance with the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated as of August 29, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Merger Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), by and among AgeX, Canaria Transaction Corporation, an Alabama corporation and a wholly owned subsidiary of AgeX (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Merger Sub</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and Serina Therapeutics, Inc., an Alabama corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Legacy Serina</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), pursuant to which Merger Sub merged with and into Legacy Serina, with Legacy Serina surviving the merger as a wholly owned subsidiary of AgeX (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Merger</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Additionally, on March 26, 2024, AgeX changed its name from &#8220;AgeX Therapeutics, Inc.&#8221; to &#8220;Serina Therapeutics, Inc.&#8221;</font></div><div style="margin-bottom:11pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">L.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.54pt">Seller and Buyer are each aware that, as a result of the transactions described above, all of the assets of the Company and its subsidiaries are currently encumbered by the obligations arising from the Secured Notes, the Secured Note Loan Documents, the Guaranties, and the Subsidiary Security Agreements, as each of such documents may have been amended by the Convertible Notes Agreement, and all subsequent amendments and allonges to Secured Notes and the Secured Note Loan Documents.  </font></div><div style="margin-bottom:11pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">M.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.47pt">Seller owns all of the issued and outstanding shares of common stock, $.001 par value (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) of the Company.</font></div><div style="margin-bottom:11pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">N.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:7.31pt">Seller wishes to sell to Buyer, and Buyer wishes to purchase from Seller, the Shares, subject to the terms and conditions set forth herein&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows&#58;</font></div><div style="margin-bottom:12pt;margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.88pt"><br>PURCHASE AND SALE</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Purchase and Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to the terms and conditions set forth herein, at the Closing, Seller shall sell to Buyer, and Buyer shall purchase from Seller, the Shares, free and clear of any lien, pledge, mortgage, deed of trust, security interest, charge, claim, easement, encroachment or other encumbrance (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Encumbrance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The aggregate purchase price for the Shares shall be $10.00 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Buyer shall pay the Purchase Price to Seller at the Closing by check made payable to Seller or by wire transfer of immediately available funds to an account specified by Seller. </font></div><div style="margin-bottom:12pt;margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.6pt"><br>CLOSING</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 2.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The closing of the transactions contemplated by this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) shall take place simultaneously with the execution of this Agreement and the execution hereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) remotely by exchange of documents and signatures (or their electronic counterparts). The consummation of the transactions contemplated by this Agreement shall be deemed to occur at 11&#58;59 pm on December 23, 2024 (Central Standard Time) on the Closing Date.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 2.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Seller Closing Deliverables</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">At the Closing, Seller shall deliver to Buyer the following&#58;</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">this Agreement, duly executed by the Seller&#59;</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">an irrevocable stock power to effectuate the transfer of the Shares, in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, duly executed by the Seller&#59;</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">a certificate of the Secretary of Seller certifying&#58; (i) that attached thereto are true and complete copies of all resolutions of the board of directors of Seller authorizing the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby, and that such resolutions are in full force and effect&#59; (ii) the names, titles and signatures of the officers of Seller authorized to sign this Agreement&#59; and (iii) that attached thereto are true and complete copies of the governing documents of the Company, including any amendments or restatements thereof, and that such governing documents are in full force and effect&#59; and</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">a certificate pursuant to Treasury Regulations Section 1.1445-2(b) that Seller is not a foreign person within the meaning of Section 1445 of the Internal Revenue Code of 1986 (as amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 2.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Buyer&#8217;s Deliveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. At the Closing, Buyer shall deliver the following to Seller&#58;</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">this Agreement, duly executed by the Buyer&#59;</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">the Purchase Price pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#59; and</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">a certificate of the Secretary (or other officer) of Buyer, dated as of the Closing Date, certifying&#58; (i) that attached thereto are true and complete copies of all resolutions of the board of directors of Buyer authorizing the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby, and that such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">resolutions are in full force and effect&#59; and (ii) the names, titles and signatures of the officers of Buyer authorized to sign this Agreement.</font></div><div style="margin-bottom:12pt;margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE III</font></div><div style="margin-bottom:12pt;margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE IV</font></div><div style="margin-bottom:12pt;margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:11.22pt"><br>REPRESENTATIONS AND WARRANTIES OF SELLER</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Seller represents and warrants to Buyer that the statements contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> are true and correct as of the date hereof. </font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 5.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Organization and Authority of Seller</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each of the Seller, the Company, and Reverse Bio is a corporation duly organized and validly existing under, and by virtue of, the laws of the State of Delaware and is in good standing under such laws. ReCyte is a corporation duly organized and validly existing under, and by virtue of, the laws of the State of California and is in good standing under such laws Seller has the requisite corporate power and authority to enter into this Agreement, and to sell the Shares and carry out and perform its other obligations under the terms of this Agreement</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 5.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All corporate action on the part of the Seller and its Affiliates and its directors, officers and stockholders necessary for the authorization, execution, delivery and performance of all obligations of the Seller under this Agreement and any other Transaction Document (as defined in</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> Section 6.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) for the sale, transfer, and assignment of the Shares has been taken. This Agreement and the other Transaction Documents constitute the valid and binding obligations of the Seller and are enforceable against the Seller in accordance with their respective terms, except as enforceability may be limited by bankruptcy, insolvency or other laws affecting the enforcement of creditors&#8217; rights generally, and except that the availability of the remedy of specific performance or other equitable relief is subject to the discretion of the court before which any proceeding therefor may be brought. Except for the perfection of the transfer of the intellectual property assets of the Company (as described in Recital C) with the applicable Governmental Body and except as anticipated and described in Section 1.3 of the Asset Contribution Agreement, no consent, approval, license, order, authorization, registration, declaration or filing with or of any Governmental Body or other Person is required to be done or obtained by the Seller or any of its Affiliates in connection with (i)&#160;the execution and delivery by the Seller of this Agreement and the other Transaction Documents, (ii)&#160;the performance by the Seller of its obligations under this Agreement or (iii)&#160;the consummation by the Seller of any of the transactions contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 5.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Capitalization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> </font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">(i) The authorized capital stock of the Company consists of 1,000 shares of common stock, $.001 par value, of which 1,000 shares are issued and outstanding in uncertificated format and constitute the Shares. To the knowledge of Seller, all of the Shares have been duly authorized, are validly issued, fully paid and non-assessable. All of the Shares are owned of record and beneficially by Seller, free and clear of all Encumbrances. </font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.02pt">(ii) The authorized capital stock of Reverse Bio consists of (A) 100,000,000 shares of common stock, $.0001 par value, of which 1,000 shares are issued and outstanding (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reverse Bio Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and (B) 5,000,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shares of preferred stock, $.0001 par value, of which no shares are issued and outstanding. To the knowledge of Seller, all of the issued and outstanding Reverse Bio Common Stock has been duly authorized, are validly issued, fully paid and non-assessable. The Company is the record and beneficial owner of all of the issued and outstanding Reverse Bio Common Stock subject to the Encumbrances arising from the Secured Notes, the Secured Note Loan </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Documents, the Guaranties, and the Subsidiary Security Agreements, as each of such documents may have been amended by the Convertible Notes Agreement, and all subsequent amendments and allonges to Secured Notes and the Secured Note Loan Documents. </font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii) The authorized capital stock of ReCyte consists of (A) 50,000,000 shares of common stock, no stated par value, of which 25,304,904 shares are issued and outstanding (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ReCyte Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and (B) 5,000,000 shares of preferred stock with no stated par value, of which no shares are issued and outstanding. To the knowledge of Seller, all of the issued and outstanding ReCyte Common Stock has been duly authorized, are validly issued, fully paid and non-assessable. The Company is the record and beneficial owner of 24,000,000 share of the Recyte Common Stock subject to the Encumbrances arising from the Secured Notes, the Secured Note Loan Documents, the Guaranties, and the Subsidiary Security Agreements, as each of such documents may have been amended by the Convertible Notes Agreement, and all subsequent amendments and allonges to Secured Notes and the Secured Note Loan Documents. To the knowledge of the Seller, Life Extension Foundation is the record and beneficial owner of 973,710 shares of the Recyte Common Stock&#59; Geothermal Core, SA (100% owned by Steve Reilly) is the record and beneficial owner of 331,169</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shares of the Recyte Common Stock&#59; and Robert W. Peabody</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">is the record and beneficial owner of 25 shares of the Recyte Common Stock.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">(i)  There are no outstanding or authorized options, warrants, convertible securities, stock appreciation, phantom stock, profit participation or other rights, agreements or commitments relating to the Shares of the Company or obligating Seller or the Company to issue or sell any shares of, or any other interest in, the Company. There are no voting trusts, stockholder agreements, proxies, or other agreements in effect with respect to the voting or transfer of any of the Shares.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.02pt">(ii) To the knowledge of Seller, there are no outstanding or authorized options, warrants, convertible securities, stock appreciation, phantom stock, profit participation or other rights, agreements or commitments relating to the Reverse Bio Common Stock or the ReCyte Common Stock or any obligation of the Company, Reverse Bio or ReCyte to issue or sell any shares of, or any other interest in, Reverse Bio or ReCyte. To the knowledge of Seller, there are no voting trusts, stockholder agreements, proxies, or other agreements in effect with respect to the voting or transfer of any of the Reverse Bio Common Stock or ReCyte Common Stock.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 5.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">No Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The execution, delivery and performance of this Agreement and the other Transaction Documents, and the consummation of the transactions contemplated hereby and thereby and compliance with the provisions hereof and thereof, by the Seller or the Company, as applicable, will not (a) violate any provision of law, statute, rule or regulation, or any ruling, writ, injunction, order, judgment or decree of any court, administrative agency or Governmental Body applicable to the Seller, the Company, the Shares or any of the Seller&#8217;s or the Company&#8217;s properties or other assets or (b) with due notice or lapse of time, or both, violate, conflict with or result in any breach of any of the terms, conditions or provisions of, or constitute a default (or give rise to any right of termination, cancellation or acceleration) under, or result in the creation of any Encumbrance upon any of the properties or other assets of the Seller or the Company under, its governing documents or any note, indenture, mortgage, lease agreement or other contract, agreement or instrument to which the Seller or the Company is a party or by which it or any of its properties is bound or affected. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Governmental Body</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any&#58; (a) nation, principality, republic, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature&#59; (b) federal, state, local, municipal, foreign or other government&#59; (c) governmental or quasi-governmental authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, board, instrumentality, officer, official, representative, organization, unit, body or other entity and any court, arbitrator or other tribunal)&#59; (d) multi-national organization or body&#59; or (e) individual, body or other entity exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 5.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The only assets of the Company are the assets that were contributed to the Company pursuant to the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset Contribution Agreement. Since the Effective Time of the Merger, Seller has not encumbered the properties or other assets of the Company and there are no Encumbrances on any of the Company&#8217;s properties or other assets other than those Encumbrances arising from the Secured Notes, the Secured Note Loan Documents, the Guaranties, and the Subsidiary Security Agreements, as each of such documents may have been amended by the Convertible Notes Agreement, and all subsequent amendments and allonges to Secured Notes and the Secured Note Loan Documents.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 5.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">To the knowledge of Seller, the only liabilities and&#47;or payables of the Company are (i) the obligations owed to the Buyer under the Secured Notes Loan Documents and Subsidiary Security Agreements, (ii) the ongoing costs of maintaining and perfecting the intellectual property assets of the Company, (iii) the ongoing cost of maintaining the other assets of the Company, (iv) the ongoing expense of the employee of the Company, (iv) the liabilities and obligations under the Asset Contribution Agreement, (v) the liabilities and obligations under and Secured Notes, the Secured Note Loan Documents, the Guaranties, and the Subsidiary Security Agreements, as each of such documents may have been amended by the Convertible Notes Agreement, and all subsequent amendments and allonges to Secured Notes and the Secured Note Loan Documents, and (vi) the ongoing costs of maintaining the Company&#8217;s existence. </font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 5.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. None of the Seller, its Affiliates, the Company or the Subsidiary Obligors are party to any action and there is no action pending or, to the knowledge of the Seller, threatened, against the Seller or the Company, or its subsidiaries which, (i) if adversely determined, would prevent the consummation of the transactions contemplated by this Agreement or otherwise have a materially adverse effect on the Company, the Subsidiary Obligors, the Shares, the Company&#8217;s properties or other assets or the transactions contemplated by this Agreement (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) or (ii) involves or relates to the Shares or the Company&#8217;s properties or other assets.  None of the Seller, its Affiliates or the Company has received any written notice of, any action, claim, suit, investigation or proceeding pending or threatened before any Governmental Body and, to the knowledge of the Seller, no such action, claim, suit, investigation or proceeding has been threatened against the Seller or any of its Affiliates, the Company, the Shares that, either individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 5.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">No Other Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except for the representations and warranties contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, none of Seller, the Company or any other Person has made or makes any other express or implied representation or warranty, either written or oral, on behalf of Seller or the Company, including any representation or warranty as to the accuracy or completeness of any information regarding the Company furnished or made available to Buyer (including any information, documents or material delivered to Buyer, or any management presentations made in expectation of the transactions contemplated hereby) or as to the future revenue, profitability or success of the Company, or any representation or warranty arising from statute or otherwise in law.</font></div><div style="margin-bottom:12pt;margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:6.94pt"><br>REPRESENTATIONS AND WARRANTIES OF BUYER</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Buyer represents and warrants to Seller that the statements contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> are true and correct as of the date hereof.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 6.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Organization and Authority of Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Buyer is a private limited company incorporated under the laws of the Isle of Man and is in good standing under such laws. Buyer has the requisite corporate power and authority to enter into this Agreement, and to purchase the Shares and carry out and perform its other obligations under the terms of this Agreement.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 6.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Buyer has full power and authority to enter into this Agreement. This Agreement, when executed and delivered by Buyer, will constitute valid and legally binding obligations of Buyer, enforceable against Buyer in accordance with their terms, except as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance and any other laws of general application affecting enforcement of creditors&#8217; rights generally, and as limited by laws relating </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to the availability of specific performance, injunctive relief or other equitable remedies. No consent, approval, license, order, authorization, registration, declaration or filing with or of any Governmental Body or other Person is required to be done or obtained by the Buyer or any of its Affiliates in connection with (i)&#160;the execution and delivery by the Buyer of this Agreement, (ii)&#160;the performance by the Buyer of its obligations under this Agreement or (iii)&#160;the consummation by the Buyer of any of the transactions contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 6.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Purchase Entirely for Own Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement is made with Buyer in reliance upon Buyer&#8217;s representation to the Seller, which by Buyer&#8217;s execution of this Agreement, Buyer hereby confirms, that the Shares to be acquired by Buyer will be acquired for investment for Buyer&#8217;s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that Buyer has no present intention of selling, granting any participation in, or otherwise distributing the same. By executing this Agreement, Buyer further represents that Buyer does not presently have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or to any third person, with respect to any of the Shares. Buyer has not been formed for the specific purpose of acquiring the Shares.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 6.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Investment Purpose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Buyer is acquiring the Shares solely for its own account for investment purposes and not with a view to, or for offer or sale in connection with, any distribution thereof or any other security related thereto within the meaning of the Securities Act of 1933, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Buyer acknowledges that Seller has not registered the offer and sale of the Shares under the Securities Act or any state securities laws, and that the Shares may not be pledged, transferred, sold, offered for sale, hypothecated or otherwise disposed of except pursuant to the registration provisions of the Securities Act or pursuant to an applicable exemption therefrom and subject to state securities laws and regulations, as applicable. Buyer is able to bear the economic risk of holding the Shares for an indefinite period (including total loss of its investment), and has sufficient knowledge and experience in financial and business matters so as to be capable of evaluating the merits and risk of its investment.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 6.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Accredited Investor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Buyer is an accredited investor as defined in Rule 501(a) of Regulation D promulgated under the Securities Act.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 6.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Foreign Investors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If Buyer is not a United States person (as defined by Section 7701(a)(30) of the Code), Buyer hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the Shares or any use of this Agreement, including (i) the legal requirements within its jurisdiction for the purchase of the Shares, (ii) any foreign exchange restrictions applicable to such purchase, (iii) any governmental or other consents that may need to be obtained, and (iv) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale, or transfer of the Shares. Buyer&#8217;s purchase of and continued beneficial ownership of the Shares will not violate any applicable securities or other laws of Buyer&#8217;s jurisdiction.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 6.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Legal Proceedings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. There is no action pending or, to the knowledge of Buyer, threatened, against Buyer or its Affiliates which, if adversely determined, would prevent the consummation of or otherwise have a material and adverse effect on the transactions contemplated by this Agreement. None of the Buyer or its Affiliates has received any written notice of, any action, claim, suit, investigation or proceeding pending or threatened before any Governmental Body and, to the knowledge of the Buyer, no such action, claim, suit, investigation or proceeding has been threatened against the Buyer or any of its Affiliates that, either individually or in the aggregate, has had or would reasonably be expected to have a material adverse effect on the Buyer&#8217;s ability to consummate the transactions contemplated by this Agreement. </font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 6.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Sophistication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Buyer (either alone or together with its advisors) has such knowledge and experience in financial or business matters and in investments of this type that it is capable of evaluating the merits and risks of the transaction contemplated by this Agreement. Buyer has had the opportunity to ask questions and receive answers concerning the terms and conditions of such transaction as it has requested. Buyer has received all information that it believes is necessary or appropriate in connection with the transaction contemplated by this Agreement. Buyer acknowledges that it has not relied upon any express or implied representations or warranties of any nature made by or on </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">behalf of the Seller, whether or not any such representations, warranties or statements were made in writing or orally, except as expressly set forth for the benefit of Buyer in this Agreement.</font></div><div style="margin-bottom:12pt;margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:2.66pt"><br>OTHER AGREEMENTS</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 7.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Assets Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 7.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.03pt">(a) Buyer and Seller agree that Seller has limited knowledge and experience regarding the Company&#8217;s assets and, except as set forth in Article III (and giving effect to Recital D), Seller has not made any representation or warranty in respect thereto and Seller hereby specifically disclaims any and all warranties, express or implied, regarding any of the assets of the Company. Buyer understands that the Company&#8217;s assets are in &#8220;as is&#8221; &#8220;where is&#8221; condition and that the assets of the Company are fully encumbered by obligations under the Convertible Notes Agreement, the 2022 Note, and all amendments and allonges thereto, the 2023 Note, and all amendments and allonges thereto, the Secured Notes Loan Documents, and other related agreements as the Buyer is the lender with respect to the obligations of the Company under those agreements.  </font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 7.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.03pt">(b) Buyer and Seller agree that Seller has informed Buyer that, at the time the assets of the Company were contributed to the Company by AgeX pursuant to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Asset Contribution Agreement, the transfer of certain intellectual property assets was not perfected with the applicable Governmental Bodies and neither AgeX nor Seller has taken any steps to perfect that transfer. Seller agrees to cooperate with Buyer after the consummation of the transactions contemplated herein by executing and delivering such documents, certificates, agreements and other writings and to take such other actions, in each case as Buyer reasonably requests to perfect the transfer of the intellectual property assets with the appropriate Governmental Bodies and to otherwise give effect to the transactions contemplated by this Agreement, but the parties agree that any such actions requested by the Buyer will be at the cost of the Buyer.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 7.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Claim Reserve</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Buyer, Seller and Juvenescence agree that Section 12 of the Convertible Notes Agreement is hereby incorporated herein by reference, except that the last sentence of Section 12 shall be deemed to be deleted. All funds to be provided to Seller by Juvenescence pursuant to the provisions of Section 12 of the Convertible Notes Agreement as incorporated herein for any claims described therein shall be paid directly to Seller by Juvenescence.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 7.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Resignations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The parties agree that, effective as of the Closing Date, all of the officers and directors of the Company, ReCyte, and Reverse Bio, other than Greg Bailey and Richard Marshall shall resign from their positions as officers and&#47;or directors (as applicable) of the Company, ReCyte, and Reverse Bio.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 7.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Closing Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The parties agree all obligations created under Section 13 of the Convertible Notes Agreement have been completed and neither party owes the other party any further obligations thereunder. </font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 7.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Mutual Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:11pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Release by Buyer and Related Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except for the obligations of the Seller arising under this Agreement and any losses suffered or incurred by the Buyer arising from a breach of any provisions by the Seller under this Agreement or any other Transaction Document, the Buyer for itself and on behalf of its Affiliates (including, but not limited to, Juvenescence) and their respective  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:11pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">successors, assigns, members, managers, partners, directors, officers,  and agents (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Buyer Releasing Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) does, by the execution of this Agreement, completely release, remise, and forever discharge the Seller, the Seller&#8217;s Affiliates (other than the Company and its subsidiaries), and their respective successors, assigns, members, stockholders, managers, partners, officers, directors, employees, and agents (collectively and respectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Seller Released Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) from any and all claims, demands, causes of action, liabilities, damages, expenses and suits of every kind and nature, whether known, unknown, or unknowable, which any such Buyer Releasing Party or anyone claiming through or under such  Buyer Releasing Party, ever had, now has, or may in the future have or acquire against any of the Seller Released Parties for, upon, or by reason of or relating to any matter, action, agreement, understanding, arrangement, transaction, omission, practice, conduct, cause or thing, act or failure to act whatsoever from the beginning of time through the Closing Date with respect to the Company and the Company&#8217;s assets and liabilities, the Asset Contribution Agreement,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Convertible Notes Agreement, the 2022 Note, and all amendments and allonges thereto, the 2023 Note and all amendments and allonges thereto and the Secured Notes Loan Documents. </font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Release by Seller</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except for the obligations of the Buyer arising under this Agreement and any losses suffered or incurred by the Seller arising from a breach of any provisions by the Buyer under this Agreement or any other Transaction Document, the Seller, for itself and on behalf of its Affiliates (other than the Company and its subsidiaries) and their respective successors, assigns, members, managers, partners, directors, officers, and agents (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Seller Releasing Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) does, by the execution of this Agreement, completely release, remise, and forever discharge the Buyer, its Affiliates (including, but not limited to, Juvenescence) and other subsidiaries and their respective successors, assigns, members, stockholders, managers, partners, directors, officers, employees and agents (collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Buyer Released Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) from any and all claims, demands, causes of action, liabilities, damages, expenses and suits of every kind and nature, whether known, unknown, or unknowable, which any such Seller Releasing Party or anyone claiming through or under such Seller Releasing Party, ever had, now has, or may in the future have or acquire against any of the Buyer Released Parties for, upon, or by reason of or relating to any matter, action, agreement, understanding, arrangement, transaction, omission, practice, conduct, cause or thing, act or failure to act whatsoever from the beginning of time through the Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with respect to the Company and the Company&#8217;s assets and liabilities, the Asset Contribution Agreement, the Convertible Notes Agreement, the 2022 Note, and all amendments and allonges thereto, the 2023 Note, and all amendments and allonges thereto and the Secured Notes Loan Documents.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c) Buyer, Seller, and Juvenescence agree that the releases provided in Sections 5.05(a) and (b) shall be binding upon and inure to the benefit of Juvenescence. </font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d) Buyer, Seller, and Juvenescence agree that the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">releases provided in Sections 5.05(a) and (b) shall not apply to the rights and obligations of the Buyer, Seller, and Juvenescence with respect to (i) the 377,865 Incentive Warrants (as defined in the Warrant Agreement, as such term is defined in the Merger Agreement) issued to, and owned by, Buyer, (ii) that certain Agreement by and among the Buyer, Seller, and Juvenescence dated November 26, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">November 26, 2024 Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) regarding the purchase by Buyer of 1,000,000 shares of the Seller&#8217;s common stock and the issuance of 755,728 Incentive Warrants (as defined in the November 26, 2024 Agreement), and (iii) the Side Letter (as defined in the Merger Agreement), as amended by the November 26, 2024 Agreement.    </font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5.06&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Seller agrees that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">UniverXome, Reverse Bio and ReCyte have no employees.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:34.38pt"><br>MISCELLANEOUS</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 8.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement and the legal relations among the parties shall be governed by, construed, and enforced in accordance with the laws of the State of Delaware without regard to its conflict of laws rules. The parties hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Chancery Court of Delaware or, to the extent such court does not have subject matter jurisdiction, the United States District Court for the Delaware (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Delaware Courts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Courts for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) waive any objection to the laying of venue of any such action or proceeding in the Delaware Courts, and (iv) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Courts has been brought in an improper or inconvenient forum. Each party agrees that service of process upon such party in any such claim, action, or proceeding shall be effective if notice is given in accordance with the provisions of this Agreement. EACH PARTY HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY CLAIM, ACTION, OR PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER, OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY (i) CERTIFIES THAT NO REPRESENTATIVE, AGENT, OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING AGREEMENTS, CONSENTS, AND WAIVERS AND (ii) ACKNOWLEDGES THAT IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL AGREEMENTS, CONSENTS, AND WAIVERS IN THIS SECTION 6.01.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 8.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The representations, warranties, covenants, release, and agreements made herein shall survive the closing of the transactions contemplated hereby.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 8.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, assigns of the parties hereto&#59; provide that this Agreement may not be assigned by either party hereto without the prior written consent of the other party. </font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 8.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Entire Agreement&#59; Amendment&#59; Non-Reliance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> This Agreement and the other Transaction Documents and the other documents delivered pursuant hereto and thereto constitute the full and entire understanding and agreement among the parties with regard to the subjects hereof and thereof. Neither this Agreement nor any term hereof may be amended, waived, discharged or terminated orally, but only by a written instrument signed by the parties to this Agreement. Buyer acknowledges and agrees that the neither Seller nor any director, officer, or agent thereof has made or is making any representations or warranties whatsoever regarding the subject matter of this Agreement, express or implied, except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE III (and giving effect to Recital D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, and that Buyer is not relying and has not relied on any representations or warranties whatsoever regarding the subject matter of this Agreement, express or implied, except for the representations and warranties set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE III (and giving effect to Recital D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Seller acknowledges and agrees that Buyer has not made or is making any representations or warranties whatsoever regarding the subject matter of this Agreement, express or implied, except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, and that Seller is not relying and has not relied on any representations or warranties whatsoever regarding the subject matter of this Agreement, express or implied, except for the representations and warranties set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 8.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. For a notice under this Agreement to be valid, (a) the notice must be in writing and signed by the sending party, (b) the sending party must use one of the following methods of delivery&#58; (i) personal delivery&#59; (ii) registered or certified mail, in each case, return receipt requested and postage prepaid&#59; (iii) nationally or internationally recognized overnight courier, with all fees prepaid, or (c) electronic transmission including electronic mail, and (d) the notice must be addressed to the receiving party at the addresses listed below for the receiving party or to any other address designated by the receiving party in a notice in accordance with this</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> Section 6.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If to Buyer or Juvenescence, addressed as follows&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;JuvVentures (UK) Limited</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Juvenescence Limited</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with a copy to&#58;&#160;&#160;&#160;&#160;Goodwin Procter LLP</font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">100 Northern Avenue</font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Boston, MA 02210</font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attn&#58; Jacqueline Mercier</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or at such other address as Buyer shall have furnished to the Seller in writing,</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or if to the Seller, addressed as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Serina Therapeutics, Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with a copy to&#58; &#160;&#160;&#160;&#160;Bradley Arant Boult Cummings LLP</font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">200 Clinton Avenue West, Suite 900</font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Huntsville, Alabama 35801</font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attn&#58; Scott Ludwig</font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 8.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">No Finder&#8217;s Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each party represents that it neither is nor will be obligated for any finder&#8217;s fee or commission in connection with this transaction. Buyer agrees to indemnify and to hold harmless the Seller from any liability for any commission or compensation in the nature of a finder&#8217;s or broker&#8217;s fee arising out of this transaction (and the costs and expenses of defending against such liability or asserted liability) for which Buyer or any of its officers, employees or representatives is responsible. Seller agrees to indemnify and hold harmless Buyer from any liability for any commission or compensation in the nature of a finder&#8217;s or broker&#8217;s fee arising out of this transaction (and the costs and expenses of defending against such liability or asserted liability) for which the Seller or any of its officers, employees or representatives is responsible.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 8.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Construction of Certain Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The titles of the sections and subsections of this Agreement are for convenience of reference only and are not to be considered in construing this Agreement. As used in this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any individual, corporation, partnership, trust, limited liability company, association or other entity, and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Person, any Person which, directly or indirectly, controls, is controlled by or is under common control with such Person, including, without limitation, any general partner, managing member, officer, director or similar type position of such Person. As used in this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transaction Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means this Agreement and all of the schedules, exhibits, certificates, agreements and other documents contemplated hereby and thereby and delivered in connection herewith.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 8.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument. Delivery of an executed counterpart of a signature page to this Agreement or any Transaction Document by electronic mail or other electronic delivery (including, for the avoidance of doubt, by .PDF, DocuSign, email or other electronic transmission) will be treated in all manner and respects as an original agreement or instrument and will be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 8.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Fees and Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each party shall bear its own legal, accounting and other fees and expenses incurred in connection with the execution and delivery of this Agreement and the consummation of the transactions contemplated herein.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 8.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.81pt;text-decoration:underline">Incorporation of Recitals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The parties hereto acknowledge and agree that the above Recitals are true and correct in all respects and that the same are incorporated herein and made a part hereof by reference.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;SIGNATURE PAGE FOLLOWS&#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the parties have executed this Agreement as of the date first written above.</font></div><div style="text-align:justify;text-indent:4.5pt"><font><br></font></div><div style="text-align:justify;text-indent:4.5pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">JUVVENTURES (UK) LIMITED</font></div><div style="margin-bottom:12pt;margin-top:2.35pt;padding-left:252pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline"> &#47;s&#47; David Gill&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline"> David Gill&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Its&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">Director&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">JUVENESCENCE LIMITED</font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">&#47;s&#47; Gregory Bailey&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline"> Gregory Bailey&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Its&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">Executive Chair and Director&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">SERINA THERAPEUTICS, INC.</font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">&#47;s&#47; Steve Ledger&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline"> Steve Ledger&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Its&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">Chief Executive Officer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13</font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ser-20241223.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:9a5b1713-d2e0-49d4-bf5c-be109325aa8a,g:e2c6af3d-8447-4c77-a992-13dbd7e88f3c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:SER="http://serinatherapeutics.com/20241223" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://serinatherapeutics.com/20241223">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ser-20241223_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ser-20241223_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://serinatherapeutics.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ser-20241223_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:9a5b1713-d2e0-49d4-bf5c-be109325aa8a,g:e2c6af3d-8447-4c77-a992-13dbd7e88f3c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_Security12gTitle_dc83d2c3-177f-4bd8-8ac4-63a6f627d964_terseLabel_en-US" xlink:label="lab_dei_Security12gTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(g) Security</link:label>
    <link:label id="lab_dei_Security12gTitle_label_en-US" xlink:label="lab_dei_Security12gTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(g) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12gTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12gTitle" xlink:to="lab_dei_Security12gTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_8f6dfc5b-d938-4c19-be06-e9e96313e7d9_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_44d92496-1e99-4078-ab4d-f18920ee68f5_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_6915fe24-8120-4054-b737-c20595f9152a_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_NoTradingSymbolFlag_c43cc1e9-8afb-4286-8d78-7262c8c59468_terseLabel_en-US" xlink:label="lab_dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">No Trading Symbol Flag</link:label>
    <link:label id="lab_dei_NoTradingSymbolFlag_label_en-US" xlink:label="lab_dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">No Trading Symbol Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_NoTradingSymbolFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_NoTradingSymbolFlag" xlink:to="lab_dei_NoTradingSymbolFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7917c89b-0d2d-4751-9cea-c19a576906fb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_f8f8c927-26e1-4584-9889-b19062caffa7_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityBankruptcyProceedingsReportingCurrent_504b0918-7442-4689-8352-64abfb59fed6_terseLabel_en-US" xlink:label="lab_dei_EntityBankruptcyProceedingsReportingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
    <link:label id="lab_dei_EntityBankruptcyProceedingsReportingCurrent_label_en-US" xlink:label="lab_dei_EntityBankruptcyProceedingsReportingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityBankruptcyProceedingsReportingCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="lab_dei_EntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_3506eaa0-7835-4a11-be5b-3d14a8056d8e_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_ccb23d28-1792-430d-86d1-46681fa49ca4_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_3f60e69c-42bf-4860-ab75-99963e9bf1f9_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_d6c1204b-aab9-45a2-b4ff-b2995af27457_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_abd2fcbc-88f4-4433-a04e-395768331854_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Extension_446e275d-1687-4fd3-92bb-c8b0501b763d_terseLabel_en-US" xlink:label="lab_dei_Extension" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extension</link:label>
    <link:label id="lab_dei_Extension_label_en-US" xlink:label="lab_dei_Extension" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Extension" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Extension" xlink:to="lab_dei_Extension" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f9891e5b-e01a-4204-9919-652cc8b170fc_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_1675a7e5-4494-460d-b24b-f621012ffbc8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_9c77993c-1d33-435d-b7c0-298a2200e694_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_743c29c0-d853-4a55-8220-e5e9429ddac9_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentDescription_0aebd5b4-bdd7-485b-a654-2aaf2d1929bd_terseLabel_en-US" xlink:label="lab_dei_AmendmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Description</link:label>
    <link:label id="lab_dei_AmendmentDescription_label_en-US" xlink:label="lab_dei_AmendmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Description</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentDescription" xlink:to="lab_dei_AmendmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_e51021b2-4efa-46ae-bb73-fbc03e5a774b_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_89c74722-d255-4a0a-9111-12773beeea1e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d771acc8-0082-408c-9ab1-f37e3f808e62_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_OtherReportingStandardItemNumber_6c39fe61-eb4e-4973-a0d3-c37890974f19_terseLabel_en-US" xlink:label="lab_dei_OtherReportingStandardItemNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
    <link:label id="lab_dei_OtherReportingStandardItemNumber_label_en-US" xlink:label="lab_dei_OtherReportingStandardItemNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_OtherReportingStandardItemNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_OtherReportingStandardItemNumber" xlink:to="lab_dei_OtherReportingStandardItemNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_2f6fd88d-6f5c-41c8-a615-197334b3cbb1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine3_cf162fa8-a1ec-41db-863a-65cd840b21e8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Three</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine3_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine3" xlink:to="lab_dei_EntityAddressAddressLine3" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_5e208fc4-18a6-4e0e-b00e-faf14677efd6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_0a8ec542-fbdf-4864-b84c-76a223d9d926_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAccountingStandard_5d588d6b-8d18-4372-b9fb-bcaab5ea0f5e_terseLabel_en-US" xlink:label="lab_dei_DocumentAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Accounting Standard</link:label>
    <link:label id="lab_dei_DocumentAccountingStandard_label_en-US" xlink:label="lab_dei_DocumentAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Accounting Standard</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAccountingStandard" xlink:to="lab_dei_DocumentAccountingStandard" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_23a8b26b-58b8-474a-998c-95610e85c0c4_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e477b8b5-9f74-467e-938d-57d1d7059dd0_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodStartDate_13fba1b5-69fc-4007-9989-b45a783c0498_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodStartDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period Start Date</link:label>
    <link:label id="lab_dei_DocumentPeriodStartDate_label_en-US" xlink:label="lab_dei_DocumentPeriodStartDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period Start Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodStartDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodStartDate" xlink:to="lab_dei_DocumentPeriodStartDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditedAnnualFinancialStatements_13dbbe8c-0fbf-4a8f-884e-40b557899a7f_terseLabel_en-US" xlink:label="lab_dei_AuditedAnnualFinancialStatements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Audited Annual Financial Statements</link:label>
    <link:label id="lab_dei_AuditedAnnualFinancialStatements_label_en-US" xlink:label="lab_dei_AuditedAnnualFinancialStatements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audited Annual Financial Statements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditedAnnualFinancialStatements" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditedAnnualFinancialStatements" xlink:to="lab_dei_AuditedAnnualFinancialStatements" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_bd5e75ee-e5eb-40b5-b09a-deacf5edf375_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_8a985407-3155-4992-aeec-cae0f14aac87_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentRegistrationStatement_61e350b3-ee4e-4100-8ddf-f42ea0cd0107_terseLabel_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Registration Statement</link:label>
    <link:label id="lab_dei_DocumentRegistrationStatement_label_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Registration Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentRegistrationStatement" xlink:to="lab_dei_DocumentRegistrationStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b2cbdca8-ab60-4cd3-84a5-8476e28b15ac_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_81cc2eb1-cf68-4751-844e-cb899bccb37f_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_14cab542-9547-42b0-a594-66bb251c0268_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_27732d7a-931e-4ae3-9869-dd55b2c0402b_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_7e6e3eae-89bd-4e1a-95b8-e06ab2c9222f_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_93edf177-7680-4d88-a358-b95bf8864dce_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4b0c8c69-d0d2-441d-8f09-e1c4c80f0110_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_6a3b81dd-ab94-4c1b-ac2f-b5decf1bb8f9_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_450a4e9a-404a-4853-8463-eef55647c59b_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPrimarySicNumber_cdb428be-780b-480c-9e89-28a8406e7e5e_terseLabel_en-US" xlink:label="lab_dei_EntityPrimarySicNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Primary SIC Number</link:label>
    <link:label id="lab_dei_EntityPrimarySicNumber_label_en-US" xlink:label="lab_dei_EntityPrimarySicNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Primary SIC Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPrimarySicNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPrimarySicNumber" xlink:to="lab_dei_EntityPrimarySicNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_eecadcfd-cfef-456f-a269-60e91112e88c_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentShellCompanyReport_a7643692-3d0c-476c-9460-10ffdb4825d8_terseLabel_en-US" xlink:label="lab_dei_DocumentShellCompanyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Shell Company Report</link:label>
    <link:label id="lab_dei_DocumentShellCompanyReport_label_en-US" xlink:label="lab_dei_DocumentShellCompanyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Shell Company Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentShellCompanyReport" xlink:to="lab_dei_DocumentShellCompanyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_2ec5d1cc-132d-4edb-9f5c-d84d4b6547ed_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentShellCompanyEventDate_48befd57-9e94-453e-ad4b-faaa13e1dd02_terseLabel_en-US" xlink:label="lab_dei_DocumentShellCompanyEventDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Shell Company Event Date</link:label>
    <link:label id="lab_dei_DocumentShellCompanyEventDate_label_en-US" xlink:label="lab_dei_DocumentShellCompanyEventDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Shell Company Event Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyEventDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentShellCompanyEventDate" xlink:to="lab_dei_DocumentShellCompanyEventDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_c9f5012d-241b-495f-ba3b-98f2133135b3_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_51adcf41-491c-4e29-8087-fa31b49a92d3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_a1c64876-b289-45cc-a230-7c40c9ad5dfe_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_cc7e7a31-6505-4707-9400-533caa9de01e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CountryRegion_5691d7a7-a757-4bae-ab7f-32ea0998f5e9_terseLabel_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Country Region</link:label>
    <link:label id="lab_dei_CountryRegion_label_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Country Region</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CountryRegion" xlink:to="lab_dei_CountryRegion" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_52df48db-909a-49ab-8e46-4726022fcc06_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7e19cc68-7fa2-44f9-865d-05ffce2090b6_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityReportingObligation_5d140e16-5b74-49f7-b654-22d2a35f3bfe_terseLabel_en-US" xlink:label="lab_dei_SecurityReportingObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Reporting Obligation</link:label>
    <link:label id="lab_dei_SecurityReportingObligation_label_en-US" xlink:label="lab_dei_SecurityReportingObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Reporting Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityReportingObligation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityReportingObligation" xlink:to="lab_dei_SecurityReportingObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_17f04d10-f3df-46c6-aacf-ee8efd0a4d74_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AnnualInformationForm_9250ffab-e6a3-4190-9988-375c51761c60_terseLabel_en-US" xlink:label="lab_dei_AnnualInformationForm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual Information Form</link:label>
    <link:label id="lab_dei_AnnualInformationForm_label_en-US" xlink:label="lab_dei_AnnualInformationForm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Information Form</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AnnualInformationForm" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AnnualInformationForm" xlink:to="lab_dei_AnnualInformationForm" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ser-20241223_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:9a5b1713-d2e0-49d4-bf5c-be109325aa8a,g:e2c6af3d-8447-4c77-a992-13dbd7e88f3c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://serinatherapeutics.com/role/Cover" xlink:type="simple" xlink:href="ser-20241223.xsd#Cover"/>
  <link:presentationLink xlink:role="http://serinatherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_56c712c8-f310-4caa-9b92-9f7e67b82d14" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_DocumentType_56c712c8-f310-4caa-9b92-9f7e67b82d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5ad03d8e-4fc8-4faf-9ea0-6ab28d4ec168" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_AmendmentFlag_5ad03d8e-4fc8-4faf-9ea0-6ab28d4ec168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentDescription_25573a0b-72ed-462c-8b61-f4796d046375" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_AmendmentDescription_25573a0b-72ed-462c-8b61-f4796d046375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement_c8c306a6-2e52-4bee-a6fd-977a317dbb1a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_DocumentRegistrationStatement_c8c306a6-2e52-4bee-a6fd-977a317dbb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_6dae0dcb-94ee-4a7a-9250-d272cc18d0d4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_DocumentAnnualReport_6dae0dcb-94ee-4a7a-9250-d272cc18d0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_b39af952-25f7-43cf-bec0-a1dc0dc2dce9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_DocumentQuarterlyReport_b39af952-25f7-43cf-bec0-a1dc0dc2dce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_274ac0b6-319c-4554-bacb-56aa03a8af9f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_DocumentTransitionReport_274ac0b6-319c-4554-bacb-56aa03a8af9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport_4de6faf7-87cf-4410-b22e-adbe047b9603" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_DocumentShellCompanyReport_4de6faf7-87cf-4410-b22e-adbe047b9603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyEventDate_5fa7f093-945f-4927-ab61-1eb6f45f491b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_DocumentShellCompanyEventDate_5fa7f093-945f-4927-ab61-1eb6f45f491b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodStartDate_6281b539-9aa1-4616-9351-c8f6edf1a58f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_DocumentPeriodStartDate_6281b539-9aa1-4616-9351-c8f6edf1a58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8d7195bb-cec5-47c5-8384-a7c60c6f77d5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_DocumentPeriodEndDate_8d7195bb-cec5-47c5-8384-a7c60c6f77d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5dbcf50e-19c6-4edb-b57c-54fa59a59f39" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_5dbcf50e-19c6-4edb-b57c-54fa59a59f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f3c5f1a3-aa4d-4fc3-b5c1-65f8f702ac1c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_DocumentFiscalYearFocus_f3c5f1a3-aa4d-4fc3-b5c1-65f8f702ac1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_5d48ea87-5e93-4191-a354-4b7e71049b32" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_CurrentFiscalYearEndDate_5d48ea87-5e93-4191-a354-4b7e71049b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_06f43fe1-047e-46bf-b19c-4851b63adea3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_EntityFileNumber_06f43fe1-047e-46bf-b19c-4851b63adea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b355eb6b-592c-4a2c-a1b5-56144902249e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_EntityRegistrantName_b355eb6b-592c-4a2c-a1b5-56144902249e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_40c5bd56-cd71-4e80-a7cc-4584aa992c7e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_EntityCentralIndexKey_40c5bd56-cd71-4e80-a7cc-4584aa992c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPrimarySicNumber_2ece9df3-3709-4e55-8872-1293d60a5b1c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_EntityPrimarySicNumber_2ece9df3-3709-4e55-8872-1293d60a5b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_b7f068a6-eaeb-4e2d-9e48-3af9546c900c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_EntityTaxIdentificationNumber_b7f068a6-eaeb-4e2d-9e48-3af9546c900c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5e7a7bd0-3634-4502-b507-61feb99ca577" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5e7a7bd0-3634-4502-b507-61feb99ca577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c002e4dc-e78e-492e-84a0-18672e3084ac" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_EntityAddressAddressLine1_c002e4dc-e78e-492e-84a0-18672e3084ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_e13a458f-148c-495c-840b-bcbccb398950" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_EntityAddressAddressLine2_e13a458f-148c-495c-840b-bcbccb398950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine3_962f0ecc-4f26-4080-aee7-a035be187f2b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_EntityAddressAddressLine3_962f0ecc-4f26-4080-aee7-a035be187f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ab6d27c0-5d22-41bc-ab5f-362cc48f20fb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_EntityAddressCityOrTown_ab6d27c0-5d22-41bc-ab5f-362cc48f20fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_2eecd0b9-1eee-4faf-ab60-b5fd16deaad7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_EntityAddressStateOrProvince_2eecd0b9-1eee-4faf-ab60-b5fd16deaad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_6f41c3ec-4e61-49d6-aed8-9189a4448b0b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_EntityAddressCountry_6f41c3ec-4e61-49d6-aed8-9189a4448b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bafa1399-1421-4136-b9d3-a2e390268908" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_EntityAddressPostalZipCode_bafa1399-1421-4136-b9d3-a2e390268908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion_b6f1bd41-df8e-4ba1-b342-10fa79cb2dff" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_CountryRegion_b6f1bd41-df8e-4ba1-b342-10fa79cb2dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_88adc9a5-7028-446f-9946-5cddbbea0ed2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_CityAreaCode_88adc9a5-7028-446f-9946-5cddbbea0ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4107c4db-f963-48ef-b060-e01ed55eb0d3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_LocalPhoneNumber_4107c4db-f963-48ef-b060-e01ed55eb0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Extension_615b7c54-9f8b-4316-a010-60b958c0ba9d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_Extension_615b7c54-9f8b-4316-a010-60b958c0ba9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_d2f6f318-1f9d-4d55-9835-344e9eec1726" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_WrittenCommunications_d2f6f318-1f9d-4d55-9835-344e9eec1726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_bcce1af5-5ddd-41c5-99f1-ec51f01442f9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_SolicitingMaterial_bcce1af5-5ddd-41c5-99f1-ec51f01442f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_a36286c8-e942-468e-86a1-eb2a907d2a46" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_PreCommencementTenderOffer_a36286c8-e942-468e-86a1-eb2a907d2a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_15f2eeb9-43c8-45b1-af37-ad153250ff6e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_15f2eeb9-43c8-45b1-af37-ad153250ff6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ef83d0f8-71d8-45d9-b633-1428da9f8825" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_Security12bTitle_ef83d0f8-71d8-45d9-b633-1428da9f8825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_NoTradingSymbolFlag_fd318ed5-98df-4fcb-9d8e-1d81ccc0d747" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_NoTradingSymbolFlag_fd318ed5-98df-4fcb-9d8e-1d81ccc0d747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_bd994555-c035-4ab2-96d4-c15c3483deb3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_TradingSymbol_bd994555-c035-4ab2-96d4-c15c3483deb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_9f224c4f-f552-4e34-a2b6-4ddd4859b764" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_SecurityExchangeName_9f224c4f-f552-4e34-a2b6-4ddd4859b764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12gTitle_92a37c5e-1e6e-4a4a-a97b-f49dfeb58bf3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_Security12gTitle_92a37c5e-1e6e-4a4a-a97b-f49dfeb58bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityReportingObligation_48196522-e667-47e2-bb36-d8d38f259d07" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_SecurityReportingObligation_48196522-e667-47e2-bb36-d8d38f259d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AnnualInformationForm_55bc2c91-af1e-4efd-af27-a562e05c2511" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_AnnualInformationForm_55bc2c91-af1e-4efd-af27-a562e05c2511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditedAnnualFinancialStatements_42a45218-0192-47d0-8103-e75aeca255f8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_AuditedAnnualFinancialStatements_42a45218-0192-47d0-8103-e75aeca255f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_7fee86d0-d34f-40f5-863a-986db8dbf915" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_7fee86d0-d34f-40f5-863a-986db8dbf915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_055d39c8-5188-4af9-8bd9-54a03bad99e2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_EntityVoluntaryFilers_055d39c8-5188-4af9-8bd9-54a03bad99e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_16868d8f-ce29-41dd-92f6-2eaf7c437236" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_EntityCurrentReportingStatus_16868d8f-ce29-41dd-92f6-2eaf7c437236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_26e849ea-5572-4342-96ba-63ab2f32953a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="47" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_EntityInteractiveDataCurrent_26e849ea-5572-4342-96ba-63ab2f32953a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c4169adc-e27b-4d79-9a16-c60201ab7e98" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="48" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_EntityFilerCategory_c4169adc-e27b-4d79-9a16-c60201ab7e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c209c230-d75b-48b5-9857-f446eb8cc674" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="49" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_EntitySmallBusiness_c209c230-d75b-48b5-9857-f446eb8cc674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c340ffcf-068a-4dd6-b2d3-7a81ebfec891" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_EntityEmergingGrowthCompany_c340ffcf-068a-4dd6-b2d3-7a81ebfec891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_ea5eb4d0-8694-4baf-8d81-b3d402dd9d71" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="51" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_EntityExTransitionPeriod_ea5eb4d0-8694-4baf-8d81-b3d402dd9d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard_ad02ec8a-acba-4a17-857a-4b3c117920c6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard"/>
    <link:presentationArc order="52" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_DocumentAccountingStandard_ad02ec8a-acba-4a17-857a-4b3c117920c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_OtherReportingStandardItemNumber_fa2a6bc7-014d-4ea5-809a-675e2d274892" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber"/>
    <link:presentationArc order="53" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_OtherReportingStandardItemNumber_fa2a6bc7-014d-4ea5-809a-675e2d274892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_8d22ecbf-d499-41e9-9c99-6e3809658cf4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="54" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_EntityShellCompany_8d22ecbf-d499-41e9-9c99-6e3809658cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_a720f852-6f46-4f30-aff9-e9638f0574d4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="55" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_EntityPublicFloat_a720f852-6f46-4f30-aff9-e9638f0574d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityBankruptcyProceedingsReportingCurrent_0f59ce95-d2d6-41bc-bf38-ead3f9bc2573" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent"/>
    <link:presentationArc order="56" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_EntityBankruptcyProceedingsReportingCurrent_0f59ce95-d2d6-41bc-bf38-ead3f9bc2573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_e6451fc8-0023-4764-ba47-ace2449439a8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="57" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_e6451fc8-0023-4764-ba47-ace2449439a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_d594922a-bfe4-45b3-a877-5620b30b8d09" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="58" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c7e853b-f598-45fb-bf1f-8786351f8f9f" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_d594922a-bfe4-45b3-a877-5620b30b8d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46245090718624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Dec. 13, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 23,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-38519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Serina Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001708599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-1436829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">601 Genome Way<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 2001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Huntsville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">AL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">35806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(256)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">327-9630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9
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M)$WS/(X %F>0IA@"IQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04
M" !<GI=9EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M5!B@?%.9J+SV4VPYZ8Y>9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04
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MUDX:?^:+X3]>?P%02P$"% ,4    " !<GI=9!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( %R>EUD"
MH40&[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( %R>EUF97)PC$ 8  )PG   3              "  <T!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ 7)Z76>1;(BQ]!
MMQ$  !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    ( %R>EUF?H!OPL0(  .(,   -              "  <$,
M  !X;"]S='EL97,N>&UL4$L! A0#%     @ 7)Z769>*NQS     $P(   L
M             ( !G0\  %]R96QS+RYR96QS4$L! A0#%     @ 7)Z76:K$
M(A8S 0  (@(   \              ( !AA   'AL+W=O<FMB;V]K+GAM;%!+
M 0(4 Q0    ( %R>EUDD'INBK0   /@!   :              "  >81  !X
M;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( %R>EUEED'F2
M&0$  ,\#   3              "  <L2  !;0V]N=&5N=%]4>7!E<UTN>&UL
64$L%!@     )  D /@(  !44      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ser-20241223.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://serinatherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="ser-20241223.htm">ser-20241223.htm</File>
    <File>ser-20241223.xsd</File>
    <File>ser-20241223_lab.xml</File>
    <File>ser-20241223_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="27">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ser-20241223.htm": {
   "nsprefix": "SER",
   "nsuri": "http://serinatherapeutics.com/20241223",
   "dts": {
    "inline": {
     "local": [
      "ser-20241223.htm"
     ]
    },
    "schema": {
     "local": [
      "ser-20241223.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ser-20241223_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ser-20241223_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 27
   },
   "report": {
    "R1": {
     "role": "http://serinatherapeutics.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ser-20241223.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ser-20241223.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Description",
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual Information Form",
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Audited Annual Financial Statements",
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Country Region",
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Accounting Standard",
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period Start Date",
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Registration Statement",
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Shell Company Event Date",
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Shell Company Report",
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference [Text Block]",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Three",
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Bankruptcy Proceedings, Reporting Current",
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Primary SIC Number",
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extension",
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "No Trading Symbol Flag",
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Reporting Standard Item Number",
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(g) Security",
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Reporting Obligation",
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001708599-24-000033-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001708599-24-000033-xbrl.zip
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M^ W(U+M2U]=.T;RL+ILZ-3 ^_S/LDTO5!0T_OSGGZ6'2J]!'I,Z(NR">6DR
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M@(FE&6YH$U$,]0&.[=+ <EX2?(89*YEJ!.!$D"WU9ED*[X.+T5,M7_$0;]^
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M^07)&SRPN"A8O-KS)O+:08OYQ^</-S=H.V;%R\$5KYY>VTXMRZ7W^XRGFZ>
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M2]@O6+2_8=O_9UOH#-O5G@U^ E!+ P04    " !<GI=9[XN?NU@6  "CU
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MQ'J[K)?\^_7"HN"(6H,)8 A#)U1*@"SS$B@,*:?6_1:+.*&>@LPCTM^^90_
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M*"DM&>>BM,&-XR-@%Q;C 3[;XV?W$\@>9A#14C[FN'%YGM,=<3J=XHFXQO-
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M5DNQ6I2F,+D1!C N-2 &.8E1R8"!A7#"XACCX*SVU/RE974/F!T1(S1UZHP
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MC9UXK&_S[,7;ZEVU^;)T$U]05)>."'(J1&X=:C '#++2A<\<2<(%QSI8BD-
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MN.[;,N;S0W"7(O$E17#I)8W=7MLW A^&MI"U9&AW$_O;=[AK)W9L)X*E8GE
ML%G+7 WYY\_4S(B:_>FO%V>+O4\P+-N^^WF?/:7[>]#%/K7=R<_[_SQ^3>S^
M7Y\_>?+3GPCY]\L/;_=^Z>/Z#+K5WN$ ?@5I[W.[.MU;G<+>[_WPL?WD]]XO
M_"KWPQDASS<?.^S/+X?VY'2UQRF7U\VN?SL\<UX%9I@@B0,ETB5)0E:1!&#4
M":Z\M_XO)\^ 1^VS2,1*:8B,QA#O'"=,I) ,6)M%W)QTT78?GY67X)>PA\/K
MEIL??]X_7:W.GQT<?/[\^>E%&!9/^^'D@%,J#JY;[U\UO[C3_K/8M&;.N8/-
M;[\T7;;W-<33LH-___WM43R%,T_:;KGR72P&ENVSY>;@VS[ZU4;U'_9K[\$6
MY2=RW8R40X1Q(MC3BV7:?_YD;V\KQ] OX /DO?+_/S^\^6)R"4/;>9R]P9_#
M>M7&Y=/8GQV49@>'/6*!'=Z<8'5Y#C_O+]NS\P5<'SL=(.,Q&$B96,:Y*%;_
MO/W<P5?CYP,LD9C-8-_B@:N/%R./[0A<K*!+L!WBM9U%'V\U6A2!^R^?7/@
MB\W1)D';;,[Z(BQ7@X^KAD5$2(E LG*62)4#0L@RL<9JH5BVV>7;XRX=7V+/
M-_.QA/CTI/]T@"<^*&*4-QM5-HK<,;=5YW']OOX#/,:VC=+1,!XMR8+AWT[T
MGKB ?Q0N&] F6)Z8G-3MF]9N]_KFK+X8XEX_)!AP!;DVYX=X:X;OLGO5XN#<
M#W@B$D_;1;K^=![ZLSGF:M7/H-QV6K"[^WLXZ@S# .GM=E8>'-QF9"M<5V'3
M<LJ,O\!.I]+QUPM_TBB?J$@6B,S8>YE])@X\)=H';I.$R+2=-.6WS(V:<U[O
MG#]>NUHF_1=8QJ$]+Y(W7"DC/ W$<$A$:AZ)#9J1+(W3B4HMC)IG[F]8'86
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MD;9\;[Z/I)];RG4+^<.G_O*9&5S*X=Q0O[Y4?ZBLLXF,W$R,,S6"]?VKD,"
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M97(M,C R-#$R,C,N:'1M4$L! A0#%     @ 7)Z763PB\N9G @  " <  !
M             ( !9A4  '-E<BTR,#(T,3(R,RYX<V102P$"% ,4    " !<
MGI=9[XN?NU@6  "CU   %               @ '[%P  <V5R+3(P,C0Q,C(S
M7VQA8BYX;6Q02P$"% ,4    " !<GI=939Z>Z*@-  !#?   %
M    @ &%+@  <V5R+3(P,C0Q,C(S7W!R92YX;6Q02P$"% ,4    " !<GI=9
M5#)2H$@X   WN $ '@              @ %?/   <V5R:6YA9&4M<W1O8VMP
E=7)C:&%S96%G<F4N:'1M4$L%!@     %  4 3 $  .-T      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>ser-20241223_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ser-20241223.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708599</identifier>
        </entity>
        <period>
            <startDate>2024-12-13</startDate>
            <endDate>2024-12-13</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-23">0001708599</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-24">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-12-23</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Serina Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">1-38519</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">82-1436829</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">601 Genome Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 2001</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Huntsville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">AL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">35806</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">(256)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">327-9630</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">SE</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-22">true</dei:EntityExTransitionPeriod>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-25">2024-12-23</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-26">2024-12-23</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-27">2024-12-23</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
